@Biocartis_ Company About Biocartis Vision & Mission Meet the Team Personalized Medicine Message from Our Founder Products Idylla™ About Idylla™ Idylla™ Technology Idylla™ Workflow Idylla™ Explore Idylla™ Connect Solid Biopsy Assays BRAF BRAF CE-IVD KRAS KRAS CE-IVD NRAS NRAS CE-IVD NRAS-BRAF CE-IVD NRAS-BRAF-EGFR S492R RUO EGFR EGFR CE-IVD EGFR RUO MSI MSI RUO Liquid Biopsy Assays ctBRAF ctBRAF RUO ctKRAS ctKRAS CE-IVD ctKRAS RUO ctNRAS ctNRAS-BRAF CE-IVD ctNRAS-BRAF-EGFR S492R RUO Infectious Diseases Assays Idylla™ Respiratory (IFV-RSV) Panel - CE-IVD & 510(k) Order & Support Welcome Order Access Secure Area Create Account IFUs & Operator Manual Distributors Investors Investor Overview Investors Overview Financial Information Financial Information Earnings Webcast Audio Files Shareholder Information Share Price Shareholder Meetings Corporate Governance Corporate Governance Images & Documents Document Centre Press Image Library News Registration News Registration News & Media Press Releases Images & Video Image Library Documents & Publications Did you know? Careers Biocartis DNA Vacancies Contact SAVE THE DATE Biocartis MSI Events ECP 2018 - Sep 11th ESMO 2018 - Oct 22nd REGISTER TODAY Idylla™ MSI Assay is for research use only and not for use in diagnostic procedures. Direct Access to personalized medicine Learn more about Biocartis Idylla™ Fully Automated Molecular Testing Learn more about Idylla™ Oncology See how you can guide the path her cancer takes Learn more about our assays State-of-the-art in-house cartridge manufacturing line Multimedia A passionate team driven to make a change Career Opportunities Biocartis Biocartis aims to provide direct access to personalized medicine for patients worldwide by developing fully integrated and broadly applicable molecular diagnostics. Our platforms can be used in a wide variety of healthcare settings to enable rapid and high-quality care close to patients. Learn more about Biocartis Annual Report 2017 Idylla™ Idylla™, Biocartis’ fully automated, real-time Polymerase Chain Reaction (PCR) based molecular diagnostics system, is designed to offer physicians fast access to highly reliable clinical molecular diagnostic information, anywhere and anytime. Idylla™ detects and quantifies multiple DNA or RNA-based biomarkers in a wide variety of patient sample types. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest growing and largest segments of the molecular diagnostics (MDx) market worldwide. Today, Biocartis has six oncology tests and two infectious disease tests in its offer. learn more about Idylla™ Personalized Medicine Personalized medicine is about every person’s unique genetic profile. Understanding and leveraging the molecular mechanisms underlying diseases, empowers doctors to shift away from the one-drug-fits-all paradigm and tailor a treatment to the genetic profile of their patient. Specific molecular diagnostics tests can help make treatments more effective, with better outcomes and as such, reduce healthcare costs. Learn more about Personalized Medicine Investors Biocartis is a commercial-stage, small-cap molecular diagnostics (MDx) company listed on Euronext (ticker: BCART) since April 2015. We develop highly innovative diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Our proprietary MDx Idylla™ platform, launched in September 2014, is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Our main value driver is our menu of rapid, easy and highly accurate molecular diagnostics tests, focused on oncology and infectious diseases. These areas represent respectively the fastest growing and largest segments of the MDx market worldwide. In June 2016, we were active in over 50 countries and had close to 300 Idylla™ platforms installed at clients worldwide. Learn more about Investing In Biocartis Shareholder Info Tweets by @Biocartis_ @Biocartis_ news 07 September 2017, 7:00AM H1 2017 Report (pdf) 31 July 2018, 7:00 AM PRESS RELEASE: Study Abstract on Performance of Idylla™ RAS tests Selected for Oral Presentation at 70th AACC Annual Scientific Meeting in Chicago, IL (US) 17 July 2018, 7:00 AM PRESS RELEASE: Biocartis launches innovative Idylla™ MSI Assay events Biocartis NV Generaal de Wittelaan 11 B3 2800 Mechelen Belgium Phone: +32 15 632 600 info@biocartis.com view map Privacy & Cookies Terms of use © 2018 Biocartis website: mediaclan MD-patient images: ziekenhuis AZ/Groeninge, Campus Kennedylaan, Kortrijk back to top